Research Article | Volume: 7, Issue: 3, March, 2017
Research Article | Volume: 7, Issue: 3, March, 2017
The present work mainly aims to discover novel small molecular inhibitors against important molecular target T3151 Abl mutant involved in leukemia. Five heterocyclic compounds 1-5 with N and S atoms (thiosemicarbazone, thiadiazole and thiazolidinoyl derivatives) were synthesised and characterised using spectral data. Docking study was carried out for 1-5 against the T315I Bcr-Abl mutant. The compounds 3-5 with phenothiazine pharmacophore showed promising docking score than with the derivatives having the coumarin pharmacophore 1 and 2. So the compounds 3-5 were tested for their anticancer activity against leukemic K562 cell line by trypan blue, MTT and LDH assays. Compound 5 showed marked anticancer activity and exhibited an IC50 value of 11.12 and 50.66 µg/ml against trypan blue and MTT assay respectively. Further a dose-dependent increase in LDH release was observed, confirming the antiproliferative potential of the compounds.
Subramanian V, Muhammad SA, Sundaram K, Ravi S. Novel Thiadiazole Derivatives as Bcr-Abl Tyrosine Kinase Inhibitors. J App Pharm Sci, 2017; 7 (03): 068-076.
Year
Month
Design, One-pot Synthesis and Biological Evaluation of Imidazo[2,1-b] [1,3,4] Thiadiazole Derivatives for their Anti- Tubercular and Anti-Fungal Activity
The Study of Base Catalysed Synthesis of 2-Chloro- 4-Amino-5-Flouropyrimidine from a biologically active Compound 5-Flouro Pyrimidine
S. Venkat Rao, S. K. Ameer, K.Neveen Reddy, S. D. V. V. S. Raju, Kumaraswamy S.In silico analysis of phytochemical compounds for optimizing the inhibitors of HMG CoA reductase